AU6407899A - Compositions and methods for wt1 specific immunotherapy - Google Patents

Compositions and methods for wt1 specific immunotherapy Download PDF

Info

Publication number
AU6407899A
AU6407899A AU64078/99A AU6407899A AU6407899A AU 6407899 A AU6407899 A AU 6407899A AU 64078/99 A AU64078/99 A AU 64078/99A AU 6407899 A AU6407899 A AU 6407899A AU 6407899 A AU6407899 A AU 6407899A
Authority
AU
Australia
Prior art keywords
seq
polypeptide
patient
cells
wti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64078/99A
Other languages
English (en)
Inventor
Martin Cheever
Alexander Gaiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU6407899A publication Critical patent/AU6407899A/en
Priority to AU2003257511A priority Critical patent/AU2003257511B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU64078/99A 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy Abandoned AU6407899A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003257511A AU2003257511B2 (en) 1998-09-30 2003-10-23 Compositions and methods for WT1 specific immunotherapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US09164223 1998-09-30
US27648499A 1999-03-25 1999-03-25
US09276484 1999-03-25
PCT/US1999/022819 WO2000018795A2 (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003257511A Division AU2003257511B2 (en) 1998-09-30 2003-10-23 Compositions and methods for WT1 specific immunotherapy

Publications (1)

Publication Number Publication Date
AU6407899A true AU6407899A (en) 2000-04-17

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64078/99A Abandoned AU6407899A (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Country Status (25)

Country Link
EP (1) EP1117687B1 (enExample)
JP (3) JP4243792B2 (enExample)
KR (1) KR100752065B1 (enExample)
CN (1) CN100486995C (enExample)
AR (1) AR021849A1 (enExample)
AT (1) ATE399179T1 (enExample)
AU (1) AU6407899A (enExample)
BR (1) BR9914116A (enExample)
CA (1) CA2349442C (enExample)
CZ (1) CZ20011144A3 (enExample)
DE (1) DE69938970D1 (enExample)
ES (1) ES2310052T3 (enExample)
HK (1) HK1039782B (enExample)
HU (1) HUP0103598A3 (enExample)
IL (2) IL142216A0 (enExample)
MX (1) MXPA01003344A (enExample)
MY (1) MY139226A (enExample)
NO (1) NO325839B1 (enExample)
NZ (1) NZ510600A (enExample)
PL (1) PL201881B1 (enExample)
RU (1) RU2237674C2 (enExample)
SA (1) SA00200872B1 (enExample)
TR (1) TR200101482T2 (enExample)
TW (1) TWI285648B (enExample)
WO (1) WO2000018795A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
PT1103564E (pt) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
ATE494905T1 (de) * 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JP4365784B2 (ja) * 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
EP1548028B1 (en) * 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
KR101431312B1 (ko) 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
PL2071028T3 (pl) * 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
RU2286146C1 (ru) * 2005-04-12 2006-10-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения церебральных метастазов генерализованной меланомы кожи
RU2301061C2 (ru) * 2005-04-28 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения генерализованной меланомы кожи
RU2424247C2 (ru) 2005-11-30 2011-07-20 Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка
DK2518149T3 (en) * 2006-02-22 2016-01-11 Int Inst Cancer Immunology Inc HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
ES2545457T3 (es) * 2006-10-17 2015-09-11 Oncotherapy Science, Inc. Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1
CN101573448B (zh) * 2006-12-28 2012-07-11 株式会社癌免疫研究所 Hla-a*1101限制的wt1肽及含有其的药物组合物
ES2559062T3 (es) 2007-02-27 2016-02-10 International Institute Of Cancer Immunology, Inc. Método para la activación de linfocitos T colaboradores y composición para su uso en el método
DK2918598T3 (en) * 2007-02-28 2019-04-29 The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services Brachyury polypeptides and methods of use
KR101669279B1 (ko) 2007-03-05 2016-10-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
KR101610664B1 (ko) * 2007-12-05 2016-04-08 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 백신 조성물
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2010135394A1 (en) * 2009-05-19 2010-11-25 University Of Miami Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
JP6082997B2 (ja) 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
ES2655031T3 (es) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
KR102158225B1 (ko) 2012-12-17 2020-09-21 오츠카 세이야쿠 가부시키가이샤 헬퍼 t세포의 활성화 방법
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
CN111781359A (zh) * 2013-05-13 2020-10-16 株式会社癌免疫研究所 用于预测免疫疗法的临床效果的方法
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
KR102797324B1 (ko) * 2014-12-11 2025-04-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 혈관 신생병의 면역 요법
JP6947720B2 (ja) * 2015-09-10 2021-10-13 メモリアル スローン ケタリング キャンサー センター Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法
CN116327902A (zh) * 2015-11-20 2023-06-27 纪念斯隆凯特林癌症中心 用于治疗癌症的方法和组合物
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
US20210100886A1 (en) 2017-03-30 2021-04-08 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
CN111533796A (zh) * 2017-04-10 2020-08-14 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的肽及其肽组合物
CN111527107B (zh) 2017-12-21 2024-10-01 豪夫迈·罗氏有限公司 结合hla-a2/wt1的抗体
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
WO2020067453A1 (ja) 2018-09-28 2020-04-02 大日本住友製薬株式会社 注射用組成物
TW202528332A (zh) 2019-02-28 2025-07-16 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
TW202200188A (zh) 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 用以處置癌症之醫藥組合物
EP4149534A4 (en) * 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
CN118076382A (zh) 2021-08-12 2024-05-24 株式会社癌免疫研究所 用于治疗或预防癌症的药用组合物和方法
EP4410304A4 (en) * 2021-09-24 2025-08-27 Cha Vaccine Res Institute Co Ltd CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM A TUMOR-ASSOCIATED ANTIGEN, AND AN ADJUVANT CONSISTING OF A LIPOPEPTIDE AND AN IMMUNOACTIVE SUBSTANCE, AND USE THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0453560B1 (en) * 1989-11-13 1999-05-26 Massachusetts Institute Of Technology Localization and characterization of the wilms' tumor gene
RU2100369C1 (ru) * 1992-04-22 1997-12-27 Варнер-Ламберт Компани Производные пептида или их фармацевтически приемлемые соли
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
AU3896899A (en) * 1998-05-11 1999-11-29 Salk Institute For Biological Studies, The Compositions for the treatment of tumors, and uses thereof
PT1103564E (pt) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1

Also Published As

Publication number Publication date
KR20010085861A (ko) 2001-09-07
JP2007001984A (ja) 2007-01-11
TR200101482T2 (tr) 2002-01-21
HUP0103598A3 (en) 2005-11-28
AR021849A1 (es) 2002-08-07
NZ510600A (en) 2003-12-19
EP1117687B1 (en) 2008-06-25
CN1336935A (zh) 2002-02-20
WO2000018795A9 (en) 2000-08-31
CZ20011144A3 (cs) 2002-06-12
HUP0103598A2 (hu) 2002-01-28
ES2310052T3 (es) 2008-12-16
HK1039782B (en) 2008-11-14
JP2008069172A (ja) 2008-03-27
SA00200872B1 (ar) 2007-01-30
NO20011613L (no) 2001-05-29
NO20011613D0 (no) 2001-03-29
IL142216A0 (en) 2002-03-10
ATE399179T1 (de) 2008-07-15
PL201881B1 (pl) 2009-05-29
DE69938970D1 (de) 2008-08-07
CN100486995C (zh) 2009-05-13
MXPA01003344A (es) 2004-04-21
EP1117687A2 (en) 2001-07-25
IL142216A (en) 2009-06-15
CA2349442A1 (en) 2000-04-06
PL348595A1 (en) 2002-06-03
JP4243792B2 (ja) 2009-03-25
KR100752065B1 (ko) 2007-08-28
HK1039782A1 (en) 2002-05-10
JP4235984B2 (ja) 2009-03-11
TWI285648B (en) 2007-08-21
NO325839B1 (no) 2008-07-28
RU2237674C2 (ru) 2004-10-10
WO2000018795A2 (en) 2000-04-06
JP2002525099A (ja) 2002-08-13
BR9914116A (pt) 2002-01-15
WO2000018795A3 (en) 2000-10-26
MY139226A (en) 2009-08-28
CA2349442C (en) 2012-12-04
TW200606176A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CA2349442C (en) Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en) Composition and methods for WTI specific immunotherapy
US7662386B2 (en) Compositions and methods for WT1 specific immunotherapy
AU2001296608B2 (en) Compositions and methods for WT1 specific immunotherapy
WO2001025273A2 (en) Compositions and methods for wt1 specific immunotherapy
US7144581B2 (en) Compositions and methods for WT1 specific immunotherapy
US20120301492A1 (en) Compositions and methods for wt1 specific immunotherapy
US7368119B2 (en) Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) Compositions and methods for WT1 specific immunotherapy
AU2003257511B2 (en) Compositions and methods for WT1 specific immunotherapy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted